VivoSeq
Musculoskeletal

Systemic Juvenile Idiopathic Arthritis

16

Pipeline Programs↗

4

Active Trials↗

10

Companies Involved↗

Systemic Juvenile Idiopathic Arthritis is an emerging landscape with 16 programs across 10 companies. The most active players are Kiniksa Pharmaceuticals (UK), Ltd., Italfarmaco, Novartis. 2 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

94/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kiniksa Pharmaceuticals (UK), Ltd.

1 program

Phase 1Italfarmaco logo

Italfarmaco

1 program

Phase 2Novartis logo

Novartis

3 programs

Phase 3AbbVie logo

AbbVie

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

61%

Small molecule

11 of 18 classified programs — the dominant modality here.

39%ALL OTHERSMonoclonal antibody633%Protein / enzyme16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed15 · 75%
Recruiting4 · 20%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

20 trials

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Recruiting·Sanofi logoSanofi·Phase 2·NCT02991469·51 enrolled
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·N/A·NCT05925452·221 enrolled
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Recruiting·AbbVie logoAbbVie·Phase 3·NCT05609630·90 enrolled
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT04088396·58 enrolled
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
Completed·Novartis logoNovartis·Phase 3·NCT00891046·270 enrolled
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Completed·Regeneron logoRegeneron·Phase 1·NCT01803321·24 enrolled
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Completed·Novartis logoNovartis·Phase 3·NCT00889863·177 enrolled
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
Completed·Roche logoRoche·Phase 4·NCT03301883·62 enrolled
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
Completed·Roche logoRoche·Phase 1·NCT01904292·52 enrolled
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
Completed·Roche logoRoche·Phase 3·NCT00144599·56 enrolled
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Completed·MMontefiore Medical Center·Phase 2·NCT00534495·71 enrolled
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Completed·Roche logoRoche·Phase 3·NCT00642460·112 enrolled
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
Completed·Italfarmaco logoItalfarmaco·Phase 2·NCT00570661·17 enrolled
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
Completed·Roche logoRoche·Phase 3·NCT00144612·60 enrolled
Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
Completed·SSwedish Orphan Biovitrum·N/A·NCT03932344·306 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)